jRCT2031210612Active, not recruitingNot Applicable
A Phase I/II Study of NPC-22 in Patients with Amyotrophic Lateral Sclerosis (NPC-22-4)
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Nobelpharma Co., Ltd.
- Enrollment
- 15
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized Controlled Trial
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Other
- Masking
- Double Blind
Eligibility Criteria
- Ages
- 20age old over to 80age old under (—)
- Sex
- All
Inclusion Criteria
- •The Japanese ALS patients who meet all inclusion criteria
- •(1) Patients who have provided their own written informed consent, who have complied with the requirements for participation in the study, who have undergone the medical examinations and tests specified in the study protocol, and who are able to report their symptoms, etc.
- •(2) Patients aged =>20 and =<80 years at the time of imformed consent, regardless of gender
- •(3) Patients who meet either "definite" or "probable" of the revised Airlie House diagnostic criteria for El Escorial
- •(4) Patients with drooling (salivary secretion below 3 on ALSFRS-R for more than 28 days) whose volume can be measured
Exclusion Criteria
- •(1) Patients with malignant tumors undergoing treatment
- •(2) Patients who are suffering or have a history of any skin disease or skin abnormality at the site of study drug administration (postauricular area) that may prevent evaluation or are receiving treatment at the site of study drug administration that may prevent evaluation (e.g., topical corticosteroids)
- •(3) Patients who have previously received treatment that affects the salivary glands (botulinum toxin injection, surgery, or radiation therapy)
- •(4) Patients who have received medication to treat drooling within 14 days (Day-14) prior to the start of study drug administration
- •(5) Patients with significant dental or oral lesions.
- •(6) Patients who are hypersensitive to scopolamine or atropine (belladonna alkaloid) or have a complication or a history of drug allergy
- •(7) Patients with any concurrent illnesses such as angle closure glaucoma, open angle glaucoma, benign prostatic hyperplasia, urinary retention, severe heart disease, congestive heart failure, arrhythmia, paralytic ileus, pyloric stenosis, ileus, ulcerative colitis, asthma, hyperthyroidism, epilepsy, hepatitis who are judged by the investigator or sub-investigator to be ineligible for participation in the study
- •(8) Patients with infectious diseases requiring treatment who are judged by the investigator or sub-investigator to be ineligible for participation in the study.
- •(9) Patients who are unable to cooperate with contraception from the time of obtaining consent until the end of observation
- •(10) Patients who are premenopausal (Menopause is defined here as the absence of menstruation for more than 12 months without any other medical reason)
- •(11) Patients who received another study drug within 12 weeks prior to the start of study drug administration
- •(12) Patients who are unsuitable as a subject in this study in the judgement of the principal investigator or a sub-investigator due to other reasons
Investigators
Similar Trials
Recruiting
Not Applicable
A phase II/III study of NPC-22jRCT2031240163Nobelpharma Co., Ltd.135
Completed
Phase 1
Repeated dose study of NPC-22SialorrheaJPRN-jRCT2031210169Miyoshi Katsunori16
Recruiting
Phase 1
Phase I Study of NC-2800Major depressive disorderJPRN-jRCT2071210033Hayamizu Koki104
Recruiting
Phase 2
A phase II study of NPC-15 on difficulty initiating sleep in patients with mild cognitive impairmentJapanese patients with mild cognitive impairment who has difficulty initiating sleepJPRN-jRCT2071230029Motomura Tomoko120
Recruiting
Phase 2
A phase II study of NPC-15 on difficulty initiating sleep in patients with dementiaJapanese patients with dementia who has difficulty initiating sleepJPRN-jRCT2071230030Motomura Tomoko120